RUNX3 independently or in combination with TGF-β and PTHrP may serve as a biomarker for predicting the prognosis of and potential for bone invasion in oral cancer patients, and it may also serve as a potential therapeutic target for controlling cancer invasion. Here, RUNX3 is linked to lip and oral cavity carcinoma.